Thibang Diphatlha: Testing adaptive strategies to close the gap from cervical cancer diagnosis to treatment in Botswana
Thibang Diphatlha:测试适应性策略,以缩小博茨瓦纳从宫颈癌诊断到治疗的差距
基本信息
- 批准号:10697331
- 负责人:
- 金额:$ 69.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-06 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS related cancerAddressAdoptionAppointments and SchedulesAreaBehaviorBotswanaCancer ControlCancer Control ResearchCaringCervical Cancer ScreeningCessation of lifeClinicClinicalCommunicationComplementComplexConsolidated Framework for Implementation ResearchCountryDataDeveloping CountriesDiagnosisDiagnostic ProcedureDisparityEarly DiagnosisEffectivenessEnsureEvaluationEvidence based practiceEvidence based treatmentFailureFemaleGoalsHIVHIV diagnosisHealth Services AccessibilityHigh PrevalenceHybridsIncidenceIncomeIndividualInterventionInterviewKnowledgeMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of cervix uteriMethodsModelingMotivationNational Cancer InstituteNewly DiagnosedOutcomePathologyPatientsPersonsPreventionPreventivePublic HealthPublishingRandomizedRecommendationResearchResource-limited settingSequential Multiple Assignment Randomized TrialShapesSurveysSystemTestingTheoretical modelTouch sensationTranslatingVisitarmbehavioral economicscancer carecancer diagnosiscancer therapycare coordinationclinical carecohortcomparativecontextual factorsdesigneffectiveness evaluationeffectiveness testingevidence baseimplementation costimplementation outcomesimplementation strategyimplementation trialimprovedinnovationlow and middle-income countriesmortalityoutreachoutreach clinicspatient navigationpatient outreachresponsescreeningsuccesssystem-level barrierstrial design
项目摘要
PROJECT SUMMARY
Delays and missed opportunities for timely treatment contribute significantly to disparities in cervical cancer mortality in low- and middle-income countries (LMICs) compared to high-income countries (HICs). Cervical cancer is one of the most common female cancers globally, with approximately 90% of cases and deaths occurring in LMICs, particularly those with high rates of HIV. This global disparity is partly driven by successful efforts in HICs to implement evidence-based practices focused on early detection and timeliness of care. In Botswana, a LMIC with an extremely high prevalence of HIV and cervical cancer, we identified substantial delays in cancer care from diagnosis to treatment, driven by a myriad of individual- and system-level barriers. To date, most of the implementation and cancer control research in Botswana and other LMICs has focused on prevention and screening, with limited focus on treatment following diagnosis of HIV-associated malignancies. As such, there is a critical need to identify effective strategies to ensure timely care, and to understand contextual factors that shape the response to strategies. Without this fundamental knowledge, cervical cancer will remain a public health crisis in Botswana and other LMICs. To help fill this critical gap, this study will test the effectiveness of adaptive strategies on timely treatment adoption using a Sequential Multiple Assignment Randomized Trial (SMART) design and evaluate contextual mechanisms contributing to the success or failure of each adaptive strategy using qualitative comparative analysis. The adaptive strategies are designed to target individual- and system-level determinants identified in our preliminary data, including delayed communication of results, individual and structural barriers to accessing treatment, and suboptimal care coordination between referring and cancer treatment clinics, and are supported by systematic evidence of the effectiveness of nudge strategies in clinical care. The primary implementation outcome will be adoption, defined as the initiation of treatment within 90 days. Secondary implementation outcomes include fidelity (i.e., completion of recommended treatment), reach, acceptability, implementation costs, and cancer and HIV-related clinical outcomes. The rationale for the study is that enhancing coordination, communication, and navigation through centralized outreach will both increase timely treatment adoption and be scalable and sustainable after the project is completed. This innovative study responds directly to the call by the National Cancer Institute to develop and test implementation strategies in cancer control in LMICs. Furthermore, the highly efficient design enables the comparison of different adaptive strategies within one study, helping to advance an understanding of the minimum level of intervention needed to improve and sustain cancer control in lower resource settings. If successful, these strategies can be easily translated to address other areas of cancer control. The long-term goal of this project is to decrease cervical cancer mortality in LMICs by developing and implementing effective and sustainable strategies.
项目总结
与高收入国家相比,延误和错失及时治疗的机会大大增加了低收入和中等收入国家宫颈癌死亡率的差异。宫颈癌是全球最常见的女性癌症之一,大约90%的病例和死亡发生在LMICs,特别是那些艾滋病毒感染率较高的地方。造成这一全球差距的部分原因是艾滋病毒/艾滋病控制中心成功地努力实施注重早期发现和及时护理的循证做法。在艾滋病毒和宫颈癌发病率极高的博茨瓦纳,我们发现癌症护理从诊断到治疗有很大延误,这是由无数个人和系统层面的障碍推动的。到目前为止,博茨瓦纳和其他小岛屿发展中国家的大多数实施和癌症控制研究都集中在预防和筛查上,对艾滋病毒相关恶性肿瘤确诊后的治疗的关注有限。因此,迫切需要确定有效的战略,以确保及时护理,并了解影响战略反应的背景因素。如果没有这些基本知识,子宫颈癌仍将是博茨瓦纳和其他低收入国家的公共卫生危机。为了帮助填补这一关键空白,本研究将使用序贯多任务随机试验(SMART)设计来测试适宜性策略在及时采用治疗方面的有效性,并使用定性比较分析来评估影响每种适宜性策略成败的背景机制。适应性策略旨在针对我们初步数据中确定的个人和系统层面的决定因素,包括结果沟通延迟、获得治疗的个人和结构性障碍,以及转诊和癌症治疗诊所之间的次优护理协调,并得到临床护理中轻推策略有效性的系统证据的支持。主要的实施结果将是采用,定义为在90天内开始治疗。次级实施结果包括保真度(即建议治疗的完成情况)、覆盖范围、可接受性、实施成本以及与癌症和艾滋病毒相关的临床结果。这项研究的基本原理是,通过集中外展加强协调、沟通和导航将增加治疗的及时性,并在项目完成后具有可伸缩性和可持续性。这项创新的研究直接响应了国家癌症研究所的号召,即开发和测试LMICs癌症控制的实施策略。此外,这种高效的设计能够在一项研究中比较不同的适应策略,有助于加深对在较低资源环境下改善和维持癌症控制所需的最低干预水平的理解。如果成功,这些策略可以很容易地转化为解决癌症控制的其他领域。该项目的长期目标是通过制定和实施有效和可持续的战略来降低低收入国家的宫颈癌死亡率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Surbhi Grover其他文献
Surbhi Grover的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Surbhi Grover', 18)}}的其他基金
Thibang Diphatlha: Testing adaptive strategies to close the gap from cervical cancer diagnosis to treatment in Botswana
Thibang Diphatlha:测试适应性策略,以缩小博茨瓦纳从宫颈癌诊断到治疗的差距
- 批准号:
10844698 - 财政年份:2022
- 资助金额:
$ 69.4万 - 项目类别:
Thibang Diphatlha: Testing adaptive strategies to close the gap from cervical cancer diagnosis to treatment in Botswana
Thibang Diphatlha:测试适应性策略,以缩小博茨瓦纳从宫颈癌诊断到治疗的差距
- 批准号:
10540624 - 财政年份:2022
- 资助金额:
$ 69.4万 - 项目类别:
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence
定量 HPV 病毒载量在确定宫颈癌治疗反应和复发方面的预后价值
- 批准号:
10399421 - 财政年份:2019
- 资助金额:
$ 69.4万 - 项目类别:
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence
定量 HPV 病毒载量在确定宫颈癌治疗反应和复发方面的预后价值
- 批准号:
10631906 - 财政年份:2019
- 资助金额:
$ 69.4万 - 项目类别:
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence
定量 HPV 病毒载量在确定宫颈癌治疗反应和复发方面的预后价值
- 批准号:
10380979 - 财政年份:2019
- 资助金额:
$ 69.4万 - 项目类别:
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence
定量 HPV 病毒载量在确定宫颈癌治疗反应和复发方面的预后价值
- 批准号:
9901475 - 财政年份:2019
- 资助金额:
$ 69.4万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 69.4万 - 项目类别:
Research Grant